Bruker this week announced it entered into a definitive acquisition agreement with NanoString Technologies. Under the agreement’s terms, Bruker will substantially acquire all of the assets and rights associated with NanoString’s business for approximately $392.6 million in cash and the assumption of certain liabilities. The transaction was approved under a court-supervised Chapter 11 sale process…

Schreiner MediPharm this week launched its late-stage customization capabilities for its RFID-Labels series. The new offering allows the company’s smart labels to be supplied quickly with order-specific programming for integrated RFID chips. Schreiner MediPharm’s RFID functional labels give pharmaceutical companies the flexibility and agility to provide the best possible security of supply and quality assurance…

Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for Ferring’s drug substance intravesical non-replicating gene therapy, Adstiladrin. The deal will help ensure the long-term future supply of gene therapy. Following the technology transfer, SK pharmteco will be qualified as another source for manufacturing, testing and release of the…

TriLink BioTechnologies today announced it opened its new cGMP mRNA manufacturing facility. The new 32,000 sq. ft. facility, based in San Diego, is specifically designed for mRNA manufacturing. Using the company’s mRNA manufacturing capabilities, it will support late-phase drug developers from Phase 2 to commercialization. TriLink said the opening is expected to help advance the…

Javelin Biotech today announced it appointed Jacques Banchereau as chief scientific officer, effective immediately. Banchereau has more than 35 years of experience in academic and industrial research. He has held roles such as Professor and Director of Immunological Sciences at the Jackson Laboratory for Genomic Medicine, Chief Scientific Officer at Hoffman-La Roche, CSO at Immunai,…

KBI Biopharma this week announced it appointed Jean-Baptiste Agnus as chief business officer, effective immediately. Angus has more than two decades of experience across various sectors of the biopharmaceutical industry with expertise in commercial development in biologics, small molecule APIs, antibody-drug conjugates, and cell and gene therapies. As chief business officer, Angus will lead KBI’s…

Vertex Pharmaceuticals recently announced it will acquire Alpine Immune Sciences for $4.9 billion in cash. The two companies signed a definitive agreement in which Vertex will buy the biotech company for $65 per share. The transaction was unanimously approved by both companies’ boards of directors and is anticipated to close later this year. Alpine is…

Sen-Jam Pharmaceutical this week announced it is partnering with specialty pharmaceutical manufacturer KVK-Tech for formulation and chemistry, manufacturing and controls for anti-inflammatory injectables. The partnership is the third development, manufacturing, distribution and license agreement the pair have signed. The new partnership will further advance Sen-Jam’s first injectable anti-inflammatory therapeutic, SJP-100. Sen-Jam is developing an immunomodulator…

Fujifilm Diosynth Biotechnologies is investing $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, N.C. Fujifilm initially invested $2 billion in the Holly Springs operation in 2021. The company said the investment made it one of North America’s largest end-to-end biopharmaceutical manufacturing facilities. The new expansion will create 680 new jobs in the…

Kintara Therapeutics and TuHURA recently announced they entered into a definitive merger agreement. The agreement is an all-stock transaction that will form a company with the expertise and resources needed to advance a risk-diversified late-stage oncology pipeline. The transaction is expected to close in Q3 2024. Kintara Therapeutics is a biopharmaceutical company investigating REM-001 in…